Clover Biopharmaceuticals, Ltd. (HKG:2197)
Hong Kong
· Delayed Price · Currency is HKD 2.970
+0.110 (3.85%)
Apr 29, 2026, 4:08 PM HKT
Clover Biopharmaceuticals Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Cash & Equivalents | 267.63 | 401.24 | 735.86 | 1,607 | 2,767 | Upgrade
|
| Short-Term Investments | 3.77 | - | 2.94 | 2.94 | 61.09 | Upgrade
|
| Trading Asset Securities | 14.62 | 14.78 | 14.17 | 13.93 | 30.91 | Upgrade
|
| Cash & Short-Term Investments | 286.02 | 416.02 | 752.97 | 1,624 | 2,859 | Upgrade
|
| Cash Growth | -31.25% | -44.75% | -53.64% | -43.19% | 263.55% | Upgrade
|
| Accounts Receivable | 0 | 40.99 | 24.11 | - | - | Upgrade
|
| Other Receivables | - | 24.21 | 49.6 | - | - | Upgrade
|
| Receivables | 0 | 65.21 | 73.71 | - | - | Upgrade
|
| Inventory | 9.86 | 11.03 | 696.98 | 2,384 | 768.69 | Upgrade
|
| Restricted Cash | - | 11.5 | 13.29 | 16.3 | 6.8 | Upgrade
|
| Other Current Assets | 39.95 | 159.44 | 362.58 | 365.01 | 1,442 | Upgrade
|
| Total Current Assets | 335.83 | 663.21 | 1,900 | 4,390 | 5,076 | Upgrade
|
| Property, Plant & Equipment | 94.47 | 116.18 | 162.06 | 241.74 | 222.4 | Upgrade
|
| Other Intangible Assets | 27.61 | 33.35 | 39.86 | 35 | 13.83 | Upgrade
|
| Other Long-Term Assets | - | - | - | 28.04 | 32.93 | Upgrade
|
| Total Assets | 457.92 | 812.74 | 2,101 | 4,695 | 5,346 | Upgrade
|
| Accounts Payable | 107.99 | 120.45 | 247.83 | 856.96 | 588.56 | Upgrade
|
| Accrued Expenses | - | 42.26 | 70.62 | 88.47 | 96.9 | Upgrade
|
| Short-Term Debt | - | 73.97 | 308.06 | 294.06 | - | Upgrade
|
| Current Portion of Leases | 10.61 | 12.18 | 18.54 | 23.57 | 21.48 | Upgrade
|
| Current Unearned Revenue | 1,573 | 1,612 | 1,578 | 1,555 | 1,424 | Upgrade
|
| Other Current Liabilities | 59.42 | 46.35 | 54.11 | 10.84 | 17.62 | Upgrade
|
| Total Current Liabilities | 1,751 | 1,908 | 2,277 | 2,829 | 2,148 | Upgrade
|
| Long-Term Leases | - | 3.5 | 7.85 | 36.74 | 46.44 | Upgrade
|
| Long-Term Unearned Revenue | 3.4 | 25.3 | 44.36 | 2,497 | 1,932 | Upgrade
|
| Other Long-Term Liabilities | 501.2 | 512.58 | 505.05 | - | - | Upgrade
|
| Total Liabilities | 2,255 | 2,449 | 2,834 | 5,363 | 4,127 | Upgrade
|
| Common Stock | 0.84 | 0.84 | 0.84 | 0.84 | 0.74 | Upgrade
|
| Additional Paid-In Capital | - | 8,654 | 8,621 | 8,562 | 7,972 | Upgrade
|
| Retained Earnings | - | -10,544 | -9,640 | -9,502 | -7,050 | Upgrade
|
| Treasury Stock | -0.02 | -0.03 | -0.03 | -0.04 | -0.05 | Upgrade
|
| Comprehensive Income & Other | -1,798 | 252.84 | 285.85 | 270.38 | 296.63 | Upgrade
|
| Shareholders' Equity | -1,797 | -1,636 | -732.83 | -668.14 | 1,219 | Upgrade
|
| Total Liabilities & Equity | 457.92 | 812.74 | 2,101 | 4,695 | 5,346 | Upgrade
|
| Total Debt | 10.61 | 89.64 | 334.45 | 354.37 | 67.92 | Upgrade
|
| Net Cash (Debt) | 275.41 | 326.38 | 418.52 | 1,270 | 2,791 | Upgrade
|
| Net Cash Growth | -15.62% | -22.02% | -67.04% | -54.51% | - | Upgrade
|
| Net Cash Per Share | 0.22 | 0.26 | 0.34 | 1.15 | 2.41 | Upgrade
|
| Filing Date Shares Outstanding | 1,262 | 1,297 | 1,296 | 1,293 | 1,158 | Upgrade
|
| Total Common Shares Outstanding | 1,262 | 1,297 | 1,296 | 1,293 | 1,158 | Upgrade
|
| Working Capital | -1,415 | -1,244 | -377.48 | 1,561 | 2,928 | Upgrade
|
| Book Value Per Share | -1.42 | -1.26 | -0.57 | -0.52 | 1.05 | Upgrade
|
| Tangible Book Value | -1,825 | -1,670 | -772.69 | -703.14 | 1,205 | Upgrade
|
| Tangible Book Value Per Share | -1.45 | -1.29 | -0.60 | -0.54 | 1.04 | Upgrade
|
| Buildings | - | - | 29.8 | 29.75 | 29.75 | Upgrade
|
| Machinery | - | - | 147.25 | 128.37 | 101.65 | Upgrade
|
| Construction In Progress | - | - | 25.28 | 44.08 | 32.15 | Upgrade
|
| Leasehold Improvements | - | - | 35.79 | 31.6 | 11.38 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.